Synapse - Ping Chi

Results (173)

Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study

Meeting Abstract

Zalcberg, J. R.; Heinrich, M.; George, S.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I

Meeting Abstract

Janku, F.; Chi, P.; Heinrich, M.; von Mehren, M.; Jones, R. L.; Ganjoo, K.; Trent, J.; Gelderblom, H.; Abdul Razak, A.; Gordon, M.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: A Phase I study of ripretinib

Journal Article

Janku, F.; Abdul Razak, A. R.; Chi, P.; Heinrich, M. C.; Von Mehren, M.; Jones, R. L.; Ganjoo, K.; Trent, J.; Gelderblom, H.; Somaiah, N.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

Meeting Abstract

Serrano, C.; Heinrich, M.; George, S.; Zalcberg, J.; Bauer, S.; Gelderblom, H.; Schoffski, P.; Jones, R.; Attia, S.; D'Amato, G.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial

Journal Article

Blay, J. Y.; Serrano, C.; Heinrich, M. C.; Zalcberg, J.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
Lancet Oncology (2020)

Fulltext@MSK | Save

MEK inhibitor-associated central retinal vein occlusion associated with hyperhomocysteinemia and MTHFR variants

Journal Article

Francis, J. H.; Diamond, E. L.; Chi, P.; Jaben, K.; Hyman, D. M.; Abramson, D. H.
Ocular Oncology and Pathology (2020)

Fulltext@MSK | Save

Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: A phase 2 clinical trial

Journal Article

Kelly, C. M.; Antonescu, C. R.; Bowler, T.; Munhoz, R.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Dholakia, R.; more...
JAMA Oncology (2020)

Fulltext@MSK | Save

Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)

Meeting Abstract

Chi, P.; Janku, F.; Heinrich, M.; Ganjoo, K.; Gelderblom, H.; Gordon, M.; Jones, R.; Razak, A.; Trent, J.; von Mehren, M.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

Meeting Abstract

von Mehren, M.; Serrano, C.; Bauer, S.; Gelderblom, H.; George, S.; Heinrich, M.; Schöffski, P.; Zalcberg, J.; Chi, P.; Jones, R. L.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

DNA damage response pathway alterations and clinical outcome in leiomyosarcoma

Meeting Abstract

Rosenbaum, E.; Jonsson, P.; Seier, K.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Qin, L. X.; Hensley, M. L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save